BRAF and melanoma: Despite the advances in the treatment of malignant melanoma with BRAF/MEK targeted agents and immunotherapy, a poor prognosis for advanced disease is noted and therefore cyclin-dependent kinase inhibition either as single agent or in combination with established treatment are under clinical trials [8].